← All agents | ← Research tracker
Lumbrokinase
PubChem entry
Evidence Summary
Evidence Level: Preliminary
Mechanism: Enrollment: Estimated, Sponsor Type: Other, Unknown / General
Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing: See linked studies/trials for reported doses and durations; typical protocols vary widely.
Mount Sinai RCT recruiting (NCT06511050) for microclots in Long COVID/ME-CFS. Fibrinolytic. 20-40mg 2-3x/day protocols. Low bleeding risk but caution with anticoagulants. Rigorous trial underway; currently research-only.
Related Conditions
Long COVID (no page yet) · ME/CFS (no page yet)
Clinical Trials
1 trial(s) registered
NCT06511050: Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome PHASE1 RECRUITING
Key Studies / References